在阿尔茨海默氏病中,白质的分数异构性下降在超强度之前
Pan Sun1, Zhengbo He2, Erwei Chu3
1Institute of Neurological and Psychiatric Disorders, Shenzhen Bay Laboratory, Shenzhen 518132, China.
Cell reports. Medicine
|May 21, 2025
概括
病理与阿尔茨海默氏症中的白质变性密切相关,前面是可见的白质变化. 准tau可能会在AD中保持白质完整性.
科学领域:
- 神经科学是一个神经科学.
- 神经病理学神经病理学
- 放射学 放射学是一门学科.
背景情况:
- 阿尔茨海默病 (AD) 涉及β-粉样蛋白 (Aβ) 和病理,但它们对白质 (WM) 退化的影响尚不清楚.
- 白质完整性对认知功能至关重要,它的退化是AD的标志.
- 了解Aβ,tau和WM变化之间的相互作用对于AD诊断和治疗至关重要.
研究的目的:
- 调查Aβ和tau沉积之间的关系,以及AD中微观结构 (微分异构,FA) 和宏观结构 (白质超强度,WMHs) 的白质变化.
- 在Aβ和tau病理学的不同阶段检查WM标记物的纵向变化.
- 探索血管风险因素对这些关联的影响.
主要方法:
- 利用正子发射断层扫描 (PET) 成像来量化Aβ和tau沉积在不同AD病理的参与者中.
- 从扩散张力成像中使用分数异构 (FA) 评估微观结构WM完整性.
- 在MRI扫描中通过白质超强度 (WMHs) 来量化宏观WM变化.
- 分析了基线和纵向数据,考虑血管风险因素,在独立的队列中.
主要成果:
- 在AD连续体中观察到较低的FA水平和更快的FA衰退率,特别是在tau阳性个体中.
- 沉积与增加的WMH负担和更快的WMH进展有显著的相关性,但不是反之.
- 这些发现在两个独立的研究队列中是一致的,加强了他们的稳定性.
结论:
- 病理是阿尔茨海默病中微观结构白质变性的主要驱动因素,在宏观WM变化之前.
- 这项研究强调了在WM完整性中的关键作用,表明了在AD早期干预中潜在的治疗点.
- 这些发现强调了监测WM退化和准tau清除的重要性,以保持阿兹海默症患者的大脑健康.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.在Aβ的斑块上,Aβ的斑块形成.分数异构的分数异构.这是宏观结构的宏观结构.微观结构的微观结构的纠结 的纠结白质退化 白质退化白质的超强度是白质的超强度.更多相关视频
12:50Lesion Explorer: A Video-guided, Standardized Protocol for Accurate and Reliable MRI-derived Volumetrics in Alzheimer's Disease and Normal Elderly
Published on: April 14, 2014
39.7K
13:26Measuring Connectivity in the Primary Visual Pathway in Human Albinism Using Diffusion Tensor Imaging and Tractography
Published on: August 11, 2016
12.2K
相关概念视频
Alzheimer's Disease: Overview
409
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
409
Alzheimer's Disease: Treatment
141
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
141
